Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Care Homes 1 Limited Annual Report and Financial Statements

Published

on

Reading Time: 13 minutes

EDINBURGH, Scotland–(BUSINESS WIRE)–Regulatory News:

Company Registered No: 05771789

CARE HOMES 1 LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December 2018

       
CONTENTS Page
 
OFFICERS AND PROFESSIONAL ADVISERS 1
 
DIRECTORS’ REPORT 2
 
INDEPENDENT AUDITOR’S REPORT 6
 
PROFIT AND LOSS ACCOUNT 12
 
STATEMENT OF COMPREHENSIVE INCOME 13
 
BALANCE SHEET 14
 
STATEMENT OF CHANGES IN EQUITY 15
 
NOTES TO THE FINANCIAL STATEMENTS 16
 
 

OFFICERS AND PROFESSIONAL ADVISERS

DIRECTORS:

      S P Nixon
K D Pereira
L E Roberts
 
 

COMPANY SECRETARY:

NatWest Markets Secretarial Services Limited
 
 

REGISTERED OFFICE:

250 Bishopsgate
London
England
EC2M 4AA
 
 
 

INDEPENDENT AUDITOR:

Ernst & Young LLP
Statutory Auditor
25 Churchill Place
Canary Wharf
London
E14 5EY
 
 

Registered in England and Wales

DIRECTORS’ REPORT

The directors of Care Homes 1 Limited (“the Company”) present their
annual report together with the audited financial statements for the
year ended 31 December 2018.

ACTIVITIES AND BUSINESS REVIEW

The Directors’ report has been prepared in accordance with the
provisions available to companies entitled to the small companies
exemption and therefore does not include a Strategic report.

Activity

The principal activity of the Company continues to be that of an
investment business.

The directors do not anticipate any material change in either the type
or level of activities of the Company.

The Company is a part of The Royal Bank of Scotland Group plc (“the
Group”) which provides the Company with direction and access to all
central resources it needs and determines policies in all key areas such
as finance, risk, human resources or environment. For this reason, the
directors believe that performance indicators specific to the Company
are not necessary or appropriate for an understanding of the
development, performance or position of the business. The annual reports
of The Royal Bank of Scotland Group plc review these matters on a group
basis. Copies can be obtained from Corporate Governance and Regulatory
Affairs, The Royal Bank of Scotland Group plc, Gogarburn, Edinburgh,
EH12 1HQ, the Registrar of Companies or at www.rbs.com.

Review of the year

Business review

The directors are satisfied with the Company’s performance in the year.
The Company does not currently expect to make any further significant
investments in the foreseeable future.

Financial performance

The Company’s financial performance is presented on page 13 to 16.

The operating loss for the year was £108,579 (2017: profit of £15,415).
The retained loss for the year was £108,579 (2017: profit of £15,415).

The directors do not recommend the payment of a dividend (2017: nil).

At the end of the year the Balance Sheet showed total assets of
£118,428,761 (2017: £126,376,502) including income-generating assets
comprising loans and receivables of £108,880,182 (2017: £111,846,675)
together representing an decrease of 6.29%. Total shareholders’ funds
were £7,346,566 (2017: £11,220,242).

Principal risks and uncertainties

The Company seeks to minimise its exposure to financial risks other than
credit risk.

Management focuses on both the overall balance sheet structure and the
control, within prudent limits, of risk arising from mismatches,
including currency, maturity, interest rate and liquidity. It is
undertaken within limits and other policy parameters set by the Group
Asset and Liability Management Committee (Group ALCO).

The principal risks associated with the company are as follows:

Operational risk

Operational risks are inherent in the Company’s business. Operational
risk losses occur as the result of fraud, human error, missing or
inadequately designed processes, failed systems, damage to physical
assets, improper behaviour or from external events. The key mitigating
processes and controls include risk and control assessment, scenario
analysis, loss data collection, new product approval process, key risk
indicators, notifiable events process and the self certification
process. The implementation of these processes and controls is
facilitated and overseen by operational risk teams, with internal audit
providing independent evaluation of the control framework.

Interest rate risk

Structural interest rate risk arises where assets and liabilities have
different repricing maturities.

The Company manages interest rate risk by monitoring the consistency in
the interest rate profile of its assets and liabilities, and limiting
any re-pricing mismatches.

Liquidity risk

Liquidity risk arises where assets and liabilities have different
contractual maturities. Management focuses on risk arising from the
mismatch of maturities across the balance sheet and from undrawn
commitments and other contingent obligations.

Credit risk

The objective of credit risk management is to enable the Company to
achieve appropriate risk versus reward performance whilst maintaining
credit risk exposure in line with approved appetite for the risk that
customers will be unable to meet their obligations to the Company.

The key principles of the group’s Credit Risk Management Framework are
set out below:

  • Approval of all credit exposure is granted prior to any advance or
    extension of credit;
  • An appropriate credit risk assessment of the customer and credit
    facilities is undertaken prior to approval of credit exposure. This
    includes a review of, amongst other things, the purpose of credit and
    sources of repayment, compliance with affordability tests, repayment
    history, capacity to repay, sensitivity to economic and market
    developments and risk-adjusted return;
  • Credit risk authority is delegated by the Board and specifically
    granted in writing to all individuals involved in the granting of
    credit approval. In exercising credit authority, the individuals act
    independently of any related business revenue origination; and
  • All credit exposures, once approved, are effectively monitored and
    managed and reviewed periodically against approved limits. Lower
    quality exposures are subject to a greater frequency of analysis and
    assessment.

Market risk

Market risk is the potential for loss as a result of adverse changes in
risk factors including interest rates and equity prices together with
related parameters such as market volatilities.

The Company is exposed to market risk as a result of the assets and
liabilities contained within the Company’s balance sheet. There has been
no change to the nature of the Company’s exposure to market risks or the
manner in which it manages and measures the risk.

The main component of market risk that the Company faces is interest
rate risk. The Company manages interest rate risk by monitoring the
interest rate profile of its assets and liabilities.

Going concern

The directors, having a reasonable expectation that the Company has
adequate resources to continue in operational existence for the
foreseeable future, have prepared the financial statements on a going
concern basis.

DIRECTORS AND SECRETARY

The present directors and secretary, who have served throughout the year
except where noted below, are listed on page 1.

From 1 January 2018 to date the following changes have taken place:

Secretary       Appointed       Resigned
RBS Secretarial Services Limited 23 August 2018
NatWest Markets Secretarial Services Limited 23 August 2018
 

DIRECTORS’ RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the annual report and the
financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare a Directors’ report and
financial statements for each financial year. Under that law, the
directors have elected to prepare the financial statements in accordance
with Financial Reporting Standard (FRS) 101 Reduced Disclosure
Framework, and must not approve the financial statements unless they are
satisfied that they give a true and fair view of the state of affairs at
the end of the year and the profit or loss of the Company for that
period. In preparing these financial statements, the directors are
required to:

  • select suitable accounting policies and then apply them consistently;
  • make judgements and estimates that are reasonable and prudent;
  • state whether FRS 101 has been followed; and
  • make an assessment of the Company’s ability to continue as a going
    concern.

The directors are responsible for keeping adequate accounting records
that are sufficient to show and explain the Company’s transactions and
disclose with reasonable accuracy at any time the financial position of
the Company and to enable them to ensure that Directors’ report and
financial statements comply with the requirements of the Companies Act
2006. They are also responsible for safeguarding the assets of the
Company and hence for taking reasonable steps for the prevention and
detection of fraud and other irregularities.

To the best of our knowledge, the financial statements for the year
ending 31 December 2018 for the issuer (“Care Homes 1 Limited”) have
been prepared in accordance Financial Reporting Standards 101 Reduced
Disclosure Framework, and give a true and fair view of the assets,
liabilities, financial position and profit of Care Homes 1 Limited. We
can also confirm that the Directors’ report includes a fair review of
the development and performance of the business and the position of Care
Homes 1 Limited, together with a description of the principal risks and
uncertainties that it faces.

This statement addresses section 4.a. (i) of the circular issued by the
Commission de Surveillance du Secteur Financier, Luxembourg.

DISCLOSURE OF INFORMATION TO AUDITOR

Each of the directors at the date of approval of this report confirms
that:

  • so far as they are aware, there is no relevant audit information of
    which the Company’s auditor is unaware; and
  • directors have taken all the steps that they ought to have taken to
    make themselves aware of any relevant audit information, and to
    establish that the Company’s auditor is aware of that information.

This confirmation is given and shall be interpreted in accordance with
the provisions of section 418 of the Companies Act 2006.

AUDITOR

Ernst & Young LLP has expressed its willingness to continue in office as
auditor.

Approved by the Board of Directors and signed on its behalf:

The accounts have been prepared in accordance with the provisions
applicable to companies subject to the small companies’ regime.

Director

Date:

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF CARE HOMES 1 LIMITED

Opinion

We have audited the financial statements of Care Homes 1 Limited for the
year ended 31 December 2018 which comprise Profit and loss account,
Statement of Comprehensive Income, Balance Sheet, Statement of Changes
in Equity and the related notes 1 to 13 including a summary of
significant accounting policies. The financial reporting framework that
has been applied in their preparation is applicable law and United
Kingdom Accounting Standards including FRS 101 “Reduced Disclosure
Framework (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

  • give a true and fair view of the company’s affairs as at 31 December
    2018 and of its loss for the year then ended;
  • have been properly prepared in accordance with United Kingdom
    Generally Accepted Accounting Practice; and
  • have been prepared in accordance with the requirements of the
    Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on
Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under
those standards are further described in the Auditor’s responsibilities
for the audit of the financial statements section of our report below.
We are independent of the company in accordance with the ethical
requirements that are relevant to our audit of the financial statements
in the UK, including the FRC’s Ethical Standard as applied to listed
public interest entities, and we have fulfilled our other ethical
responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and
appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in
relation to which the ISAs (UK) require us to report to you where:

  • the directors’ use of the going concern basis of accounting in the
    preparation of the financial statements is not appropriate; or
  • the directors have not disclosed in the financial statements any
    identified material uncertainties that may cast significant doubt
    about the company’s ability to continue to adopt the going concern
    basis of accounting for a period of at least twelve months from the
    date when the financial statements are authorised for issue.

Overview of our audit approach

Key audit matters      
  • Inappropriate valuation of derivatives, associated income and
    the related cash movement in cash flow hedging reserves
  • Inappropriate amortisation of the debt securities
Materiality      
  • Overall planning materiality of £1,184,288 which represents 1%
    of Total Assets
     

Key audit matters.

Key audit matters are those matters that, in our professional judgment,
were of most significance in our audit of the financial statements of
the current period and include the most significant assessed risks of
material misstatement (whether or not due to fraud) that we identified.
These matters included those which had the greatest effect on: the
overall audit strategy, the allocation of resources in the audit; and
directing the efforts of the engagement team. These matters were
addressed in the context of our audit of the financial statements as a
whole, and in our opinion thereon, and we do not provide a separate
opinion on these matters.

Risk

  Our response to the risk   Key observations communicated to those charged with governance

Inappropriate valuation of derivatives, associated income and
the related movement in cash flow hedging reserves

 

The Company has securitisation debt which was assumed by the
entity from a historical transaction when RBS acquired the Nursing
Homes Property group of companies. The entity then entered into a
floating rate deposit and a swap agreement with RBS that would
enable the entity to meet the ongoing interest obligations and
ultimate repayment obligations under the bonds. A derivative asset
is recognised in the financial statements from this transaction.

 

The valuation of the derivative instruments involves significant
judgment which also poses risk of inappropriate revenue
recognition and movements in the cashflow hedge reserves.

 

The judgement in estimating fair value of the instrument can
involve complex valuation models and significant fair value
adjustments both of which may be reliant on data inputs where
there is limited market observability.

As part of the RBS group audit, we performed trade life-cycle
product walkthroughs to confirm our understanding of RBS’s process
and controls around revenue recognition relating to financial
instruments with higher risk characteristics.

 

We tested the design and operating effectiveness of the Group’s
controls over financial instrument valuations, including
independent price verification, model approval/review, collateral
management, and income statement analysis and reporting.

 

We obtained the underlying trade contract and verified the
existence and ownership of recorded derivatives as well as the
underlying terms of the instruments and we engaged our derivative
valuation experts to test the fair value of derivatives and the
appropriate recording in the financial statements in accordance
with the entity’s accounting policies and FRS 101. With the
support from our internal financial instrument valuation
specialists, we performed an independent valuation of the interest
rate derivative.

 

We evaluated the hedging relationship and verified that all
conditions for the cash flow hedging relationships are in
accordance with the entity’s accounting policies and the Financial
Reporting Standards.

 

We have also corroborated the revenue on the derivative in the
year by independently recalculating the interest and further
ensured that reserves carried forward from prior periods and
movements in the year are appropriate.

We concluded to those charged with governance that based on the
procedures performed, we are satisfied that the derivative assets,
associated interest income and the related cash flow hedge
reserves as at 31 December 2018 are fairly stated.

 

However, we note that there was a sub-LIBOR element of
ineffectiveness identified that had been incorrectly recognised on
designation of the cash flow hedge reserve.

 

This resulted in a reclassification from the cash flow hedge
reserve to retained earnings in the current year to correct the
ineffectiveness in the reserve on designation of the hedge. This
correction was not material and therefore did not require a
restatement of 2017 balances.

         

Inappropriate amortisation of the debt securities

 

In terms of IFRS 9, financial liabilities are initially measured
at fair value and subsequently measured at amortised cost. The
amortised cost of a financial instrument is defined as the amount
at which it was measured at initial recognition minus principal
repayments, plus or minus the cumulative amortisation using the
effective interest method. The effective interest method is a
method of calculating the amortised cost of a financial instrument
(or group of instruments) and of allocating the interest expense
over the relevant period.

 

Due to the complexity of the calculation, there is a risk that the
amortisation using the effective interest rate method is
incorrectly calculated, resulting in the closing balance of the
debt security being incorrect as well as the interest recognised
in the income statement.

During the RBS group audit, we tested the design and operating
effectiveness of the Group’s key controls over the debt securities.

 

We performed the procedures below as part of our substantive
procedures;

 

We obtained the novation agreement when the entity assumed the
liability as well as the original issuance documents (prospectus)
to understand the terms of the agreements.

 

We reviewed the amortisation of the instruments using the
effective interest rate, including calculation and allocation of
the finance costs to the appropriate periods to determine the
amortised cost at year end.

 

We reviewed the contracts for compliance with terms and tested
whether the entity is meeting the agreed contractual obligations,
including coupon payments. We noted that the entity is meeting its
obligations in terms of the contract.

 

 

We concluded to those charged with governance that based on the
procedures performed, we are satisfied that the debt securities
are fairly stated and appropriate disclosures have been included
in the financial statements.

         

An overview of the scope of our audit.

Tailoring the scope

Our assessment of audit risk, our evaluation of materiality and our
allocation of performance materiality determine our audit scope for the
company. This enables us to form an opinion on the financial statements.
We consider size, risk profile, the organisation of the company and
effectiveness of controls, including controls and changes in the
business environment when assessing the level of work to be performed.

All audit work was performed directly by the audit engagement team,
except for the valuation of the derivative asset at year end, which was
valued by our valuation specialists as noted in key matters above.

Our application of materiality

We apply the concept of materiality in planning and performing the
audit, in evaluating the effect of identified misstatements on the audit
and in forming our audit opinion.

Materiality

The magnitude of an omission or misstatement that, individually or in
the aggregate, could reasonably be expected to influence the economic
decisions of the users of the financial statements. Materiality provides
a basis for determining the nature and extent of our audit procedures.

We determined materiality for the company to be £1,184,288 (2017:
£112,000), which is 1% of Total Assets (2017: 1% of Equity). The reason
for selecting this measure as the basis for our audit materiality is
that NWM Plc fully owns and fund the entity and that the entity’s assets
are designed to fund the obligations arising on the bond issuance, which
has been fully acquired by NWM Plc. We therefore consider that the
assets are the primary focus to the users of the financial statements.

During the course of our audit, we reassessed initial materiality moving
from an Equity-based measure to Total Assets. This was mainly driven by
assessing the primary focus of the users of the financial statements,
being NWM Plc directors, who are focused on the assets of the entity, as
opposed to a relatively small share capital base.

Performance materiality

The application of materiality at the individual account or balance
level.
It is set at an amount to reduce to an appropriately low
level the probability that the aggregate of uncorrected and undetected
misstatements exceeds materiality.

Based on our risk assessments, together with our assessment of the
company’s overall control environment, our judgement was that
performance materiality was 50% (2017: 50%) of our planning materiality,
namely £592,144 (2017: £56,000). We had set performance materiality at
this percentage due to audit differences identified in the prior year
audit requiring adjustments to both balances in 2017 and prior year
accounts.

Reporting threshold

An amount below which identified misstatements are considered as
being clearly trivial.

We agreed with those charged with governance that we would report to
them all uncorrected audit differences exceeding £59,214 (2017: £5,600),
which is set at 5% of planning materiality, as well as differences below
that threshold that, in our view, warranted reporting on qualitative
grounds.

We evaluate any uncorrected misstatements against both the quantitative
measures of materiality discussed above and considering other relevant
qualitative considerations in forming our opinion.

Other information

The other information comprises the information included in the
directors’ report set out on pages 2 to 5. The directors are responsible
for the other information.

Our opinion on the financial statements does not cover the other
information and, except to the extent otherwise explicitly stated in
this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our
responsibility is to read the other information and, in doing so,
consider whether the other information is materially inconsistent with
the financial statements or our knowledge obtained in the audit or
otherwise appears to be materially misstated. If we identify such
material inconsistencies or apparent material misstatements, we are
required to determine whether there is a material misstatement in the
financial statements or a material misstatement of the other
information. If, based on the work we have performed, we conclude that
there is a material misstatement of the other information, we are
required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken during the audit:

  • the information given in the directors’ report for the financial year
    for which the financial statements are prepared is consistent with the
    financial statements; and
  • the directors’ report has been prepared in accordance with applicable
    legal requirements.

Contacts

Care Homes 1 Limited

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives

Published

on

Continue Reading

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania